-The Indian Express Concerned about rising levels of air pollution in the city, the Delhi government has commissioned IIT-Kanpur to conduct a comprehensive study of pollution levels and causes. The government plans to use data to formulate a policy to control and reduce air pollution, and initiate a second-generation air action plan. Commissioned last month, the IIT-K study will be the most comprehensive study since the 2007 Central Pollution Control Board and...

-PTI Burdwan (WB): About 150 sheets, allegedly copies of petitions filed by depositors related to the Saradha chit fund scam, were found on the side of rail tracks between Kalna and Guptipara stations of Eastern Railway's Howrah-Burdwan section on Sunday. GRP sources said about 150 papers, claimed to be petitions of depositors from Murshidabad and Jharkhand, were spotted ying on the sides of the rail track at Purbo Satgachia station by local...

-The Hindustan Times Although crusader-turned-politician Arvind Kejriwal seems optimistic about his Aam Aadmi Party's (AAP) performance in the upcoming Delhi assembly polls, many voters apparently think otherwise. Many of the voters in Delhi hail Kejriwal's decision of launching the party, but they are not sure whether they would exercise their FRAnchise in favour of the newly-launched 'people's party'. According to them, the party lacks local presence, has a one-point agenda and indicates no...

-The Hindu   Ranbaxy's FRAudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its FRAudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...

-The Economic Times Indian pharmaceutical company Ranbaxy recently paid $500 million to the US government to settle civil and criminal charges for making FRAudulent statements to the US FDA and selling adulterated drugs in the US. Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, talks to ET about the five-year long investigation and the future of generic drug companies in the US. Edited Excerpts: * You think you...